Display options
Cite
Qing Y, Su R, Chen J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood. 2021;138(8):637-648doi: 10.1182/blood.2019004263.
Qing, Y., Su, R., & Chen, J. (2021). RNA modifications in hematopoietic malignancies: a new research frontier. Blood, 138(8), 637-648. https://doi.org/10.1182/blood.2019004263
Qing, Ying, et al. "RNA modifications in hematopoietic malignancies: a new research frontier." Blood vol. 138,8 (2021): 637-648. doi: https://doi.org/10.1182/blood.2019004263
Qing Y, Su R, Chen J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood. 2021 Aug 26;138(8):637-648. doi: 10.1182/blood.2019004263. PMID: 34157073; PMCID: PMC8394902.
Copy Download .nbib Format: NLM
Share it on

Blood. 2021 Aug 26;138(8):637-648. doi: 10.1182/blood.2019004263.

RNA modifications in hematopoietic malignancies: a new research frontier.

Blood

Ying Qing, Rui Su, Jianjun Chen

Affiliations

  1. Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA; and.
  2. Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope.
  3. City of Hope Comprehensive Cancer Center, and.
  4. The Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.

PMID: 34157073 PMCID: PMC8394902 DOI: 10.1182/blood.2019004263

Abstract

Protein-coding and noncoding RNAs can be decorated with a wealth of chemical modifications, and such modifications coordinately orchestrate gene expression during normal hematopoietic differentiation and development. Aberrant expression and/or dysfunction of the relevant RNA modification modulators/regulators ("writers," "erasers," and "readers") drive the initiation and progression of hematopoietic malignancies; targeting these dysregulated modulators holds potent therapeutic potential for the treatment of hematopoietic malignancies. In this review, we summarize current progress in the understanding of the biological functions and underlying mechanisms of RNA modifications in normal and malignant hematopoiesis, with a focus on the N6-methyladenosine modification, as well as discuss the therapeutic potential of targeting RNA modifications for the treatment of hematopoietic malignancies, especially acute myeloid leukemia.

© 2021 by The American Society of Hematology.

Publication Types

Grant support